

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	8626872		
<b>Application Number:</b>	10735592		
<b>International Application Number:</b>			
<b>Confirmation Number:</b>	2533		
<b>Title of Invention:</b>	5' CpG nucleic acids and methods of use		
<b>First Named Inventor/Applicant Name:</b>	Arthur M. Krieg		
<b>Correspondence Address:</b>	Helen C. Lockhart, Ph.D. Wolf, Greenfield & Sacks, P.C. 600 Atlantic Avenue - Boston MA 02210 US 6177203500 -		
<b>Filer:</b>	Helen C. Lockhart/Sarah Russe		
<b>Filer Authorized By:</b>	Helen C. Lockhart		
<b>Attorney Docket Number:</b>	C 1037.70038US01		
<b>Receipt Date:</b>	14-OCT-2010		
<b>Filing Date:</b>	11-DEC-2003		
<b>Time Stamp:</b>	14:58:08		
<b>Application Type:</b>	Utility under 35 USC 111(a)		

### **Payment information:**

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$180

RAM confirmation Number	1204									
Deposit Account	232825									
Authorized User	LOCKHART,HELEN C									
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:										
Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)										
<b>File Listing:</b>										
Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part /.zip	Pages (if appl.)					
1	Miscellaneous Incoming Letter	C103770038US01-TRN-HCL.pdf	30286 2d535e935ea65379f0c6e25a0ae8e82dd0d 51849	no	1					
<b>Warnings:</b>										
<b>Information:</b>										
2	Fee Worksheet (PTO-875)	C103770038US01-FEE-HCL.pdf	46080 278a3e8f54d80dd93c767dcdec5861db6ad d9d00	no	1					
<b>Warnings:</b>										
<b>Information:</b>										
3		C103770038US01-IDS-HCL.pdf	55610 119f3c529d26f786c8513c0cd0578dc954d3 3020	yes	5					
<b>Multipart Description/PDF files in .zip description</b>										
Document Description			Start	End						
Transmittal Letter			1	3						
Information Disclosure Statement (IDS) Filed (SB/08)			4	5						
<b>Warnings:</b>										
<b>Information:</b>										
4	NPL Documents	C103770038US01_Supp_Euro_Search_Report_8-7-2010.pdf	1637419 1bf1b77f9c858d7531ed5b2f546e53031f80 f9cd	no	10					
<b>Warnings:</b>										
<b>Information:</b>										
5	Foreign Reference	WO94008053.pdf	4762579 612979664372318d50801dad1e37b0eaaef da262	no	145					
<b>Warnings:</b>										
<b>Information:</b>										
6	Foreign Reference	WO00041720.pdf	1897584 dde97f040855d218a58405fa1195c0cb2b 124b4	no	53					
<b>Warnings:</b>										

<b>Information:</b>					
7	Foreign Reference	WO03040308.pdf	18868906 0811cc22056a56c56f3d269338d5db95f42 43186	no	110
<b>Warnings:</b>					
<b>Information:</b>					
8	Foreign Reference	WO03085110.pdf	4001571 f9ed9960119b4a096cebbbe5fd595378b8d b4e86	no	65
<b>Warnings:</b>					
<b>Information:</b>					
9	Foreign Reference	WO05013891.pdf	6453369 ec6410cc757a7aec16175cb6b8a9a0e1250 7f7ca	no	125
<b>Warnings:</b>					
<b>Information:</b>					
10	Foreign Reference	WO01051083.pdf	1833905 f97e3785425cc4a2f7107ddc9f5e978528a1 c861	no	49
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	Agrawal_Biochim_Biophys_Acta_1999_v1489_p53.pdf	17281617 6cf88839360164817d2b9bb3a47b650144d cd38f	no	16
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Azuma_et_al_Intl_Immunopharmacology_2001_v1_p1249.pdf	203350 63b26f914dea5a5ed3b9a955e78f/b2870d a3f48	no	11
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	Fearon_et_al_Euro_J_Immuno_2003_v33_p2114.pdf	887342 49294ae016692d7b5b81cbfac2ffab9fe3c5 d49	no	10
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	Ioannou_et_al_Vaccine_2002_v21_p127.pdf	10937494 f32f4b65ab50432ae48d293cab06cb30ee2 aefb4	no	11
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	Jorgensen_et_al_J_Virology_2003_v77_p11471.pdf	894985 dc0023e0e8e333e7baa3456ab176639f05a db1cd	no	10
<b>Warnings:</b>					

<b>Information:</b>					
16	NPL Documents	Krieg_et_al_Antis_Nuc_Acid_Drug_Dev_1997_v7_p115.pdf	4658593 3bc0f303497a19943b8c/95982a0b98f4ecc1750	no	9
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	Samani_et_al_Antisen_Nucl_Acid_Drug_Dev_2001_v11_p129.pdf	1148920 135bc69ca8dea848f5075da8cacad8475bd6d5d0	no	8
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	Sonehara_et_al_J_Int_and_Cyt_Res_1996_v16_p799.pdf	860892 7f236260cda536b50b2a60f1ebbd0c173b1c856e	no	5
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	Uhlmann_et_al_Meth_Enzymol_2000_v313_p268.pdf	16632419 9644fd93df88499e979fe3ff613e3d6b9ca99356	no	17
<b>Warnings:</b>					
<b>Information:</b>					
20	Foreign Reference	WO0154720.pdf	20385127 e70d88f0329059df05793ca74165b91e3ab8e153	no	39
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	Uhlmann_et_al_Exp_Opin_Biol_Ther_2001_v1_p319.pdf	412341 52950bbe2185fb1aad762fd54cf70cae93bf3033	no	10
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	Wahlestedt_et_al_Proc_Natl_Acad_Sci_2000_v97_p5633.pdf	8790009 652ffd5ec9734b3765da569c834dd2436078aac2	no	6
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	Yu_et_al_Biorg_Med_Chem_2001_v9_p2803.pdf	525649 5ba4c0ebf2c380425c40416005d995c3352e9e79	no	6
<b>Warnings:</b>					
<b>Information:</b>					
24	Fee Worksheet (PTO-875)	fee-info.pdf	30168 a17f86912b8d9ab561eb1d8edbcb3ed33fa6798	no	2
<b>Warnings:</b>					

Information:	Total Files Size (in bytes):	123236215
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p>		
<p><b><u>New Applications Under 35 U.S.C. 111</u></b></p>		
<p>If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p>		
<p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b></p>		
<p>If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>		
<p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b></p>		
<p>If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>		